Literature DB >> 29312519

Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells.

Jianfei Luo1, Ruicheng Yan1, Xiaobo He1, Jie He1.   

Abstract

Signal transducer and activator of transcription-3 (STAT3) is closely associated with tumorigenesis and is activated in tumor cells of a variety of cancers. The raised expression of cyclin D1 (CCND1) by activated STAT3 has been verified in some cancers. However, the relationship between STAT3 and CCND1 has yet to be studied in gastric cancer (GC) cells. In the present study, we found that STAT3 was constitutively activated in several GC cells together with overexpressed CCND1. In addition, IL-6 treatment enhanced the expression level of p-STAT3 and CCND1, accelerating the cell cycle progress and transferring from G1 to S phase. The increased proliferation, migration and invasion were also demonstrated by the treatment of IL-6 in HGC-27 and BGC-823 cells. While AG490 treatment, a Janus Kinase (JAK) inhibitor, showed the opposite effect. Therefore, our research demonstrated the positive correlation between p-STAT3 and CCND1 in GC cells. The constitutive activation of STAT3 and CCND1 overexpression accounted for the proliferation, migration and invasion in GC cells.

Entities:  

Keywords:  CCND1; STAT3; gastric cancer; invasion; migration; proliferation

Year:  2017        PMID: 29312519      PMCID: PMC5752917     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  27 in total

Review 1.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

2.  STAT3: a multifaceted oncogene.

Authors:  David E Levy; Giorgio Inghirami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

3.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.

Authors:  Pedro J Real; Angels Sierra; Ana De Juan; Jose C Segovia; Jose M Lopez-Vega; Jose L Fernandez-Luna
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

Review 4.  STAT3 signaling: anticancer strategies and challenges.

Authors:  Paul A Johnston; Jennifer R Grandis
Journal:  Mol Interv       Date:  2011-02

5.  Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines.

Authors:  Li Li; Peter E Shaw
Journal:  J Biol Chem       Date:  2002-02-21       Impact factor: 5.157

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.

Authors:  Z Zhong; Z Wen; J E Darnell
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

Review 8.  STAT-mediated EGFR signaling in cancer.

Authors:  Kelly M Quesnelle; Amanda L Boehm; Jennifer R Grandis
Journal:  J Cell Biochem       Date:  2007-10-01       Impact factor: 4.429

9.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma.

Authors:  Yoshiyasu Aoki; Gerald M Feldman; Giovanna Tosato
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  14 in total

1.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

2.  Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus.

Authors:  Zeina Nehme; Sébastien Pasquereau; Sandy Haidar Ahmad; Alain Coaquette; Chloé Molimard; Franck Monnien; Marie-Paule Algros; Olivier Adotevi; Mona Diab Assaf; Jean-Paul Feugeas; Georges Herbein
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

3.  p53, Cyclin-D1, β-catenin, APC and c-myc in Tumor Tissue from Colorectal and Gastric Cancer Patients with Suspected Lynch Syndrome by the Bethesda Criteria.

Authors:  Tais Fernanda Marcolino; Celia Aparecida Marques Pimenta; Ricardo Artigiani Neto; Paula Castelo; Marcelo Souza Silva; Nora Manoukian Forones; Celina Tizuko Fujiyama Oshima
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

4.  TMEM119 promotes gastric cancer cell migration and invasion through STAT3 signaling pathway.

Authors:  Peifen Zheng; Weifeng Wang; Muxi Ji; Qin Zhu; Yuliang Feng; Feng Zhou; Qiaona He
Journal:  Onco Targets Ther       Date:  2018-09-13       Impact factor: 4.147

5.  Docoxahexaenoic Acid Induces Apoptosis of Pancreatic Cancer Cells by Suppressing Activation of STAT3 and NF-κB.

Authors:  Mirae Park; Joo Weon Lim; Hyeyoung Kim
Journal:  Nutrients       Date:  2018-11-02       Impact factor: 5.717

6.  Lemon Peel Polyphenol Extract Reduces Interleukin-6-Induced Cell Migration, Invasiveness, and Matrix Metalloproteinase-9/2 Expression in Human Gastric Adenocarcinoma MKN-28 and AGS Cell Lines.

Authors:  Valentina Pagliara; Rosarita Nasso; Paola Di Donato; Ilaria Finore; Annarita Poli; Mariorosario Masullo; Rosaria Arcone
Journal:  Biomolecules       Date:  2019-12-05

7.  Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression.

Authors:  Napat Armartmuntree; Apinya Jusakul; Chadamas Sakonsinsiri; Watcharin Loilome; Somchai Pinlaor; Piti Ungarreevittaya; Chern Han Yong; Anchalee Techasen; Kanokwan Imtawil; Ratthaphol Kraiklang; Nattawan Suwannakul; Waleeporn Kaewlert; Timpika Chaiprasert; Raynoo Thanan; Mariko Murata
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

Review 8.  STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Sima Orouei; Vahideh Zarrin; Ebrahim Rahmani Moghadam; Amirhossein Zabolian; Shima Mohammadi; Kiavash Hushmandi; Yashar Gharehaghajlou; Pooyan Makvandi; Masoud Najafi; Reza Mohammadinejad
Journal:  Biology (Basel)       Date:  2020-06-12

9.  ESCC ATLAS: A population wide compendium of biomarkers for Esophageal Squamous Cell Carcinoma.

Authors:  Asna Tungekar; Sumana Mandarthi; Pooja Rajendra Mandaviya; Veerendra P Gadekar; Ananthajith Tantry; Sowmya Kotian; Jyotshna Reddy; Divya Prabha; Sushma Bhat; Sweta Sahay; Roshan Mascarenhas; Raghavendra Rao Badkillaya; Manoj Kumar Nagasampige; Mohan Yelnadu; Harsh Pawar; Prashantha Hebbar; Manoj Kumar Kashyap
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

10.  Activated STAT3 Could Reduce Survival in Patients with Esophageal Squamous Cell Carcinoma by Up-regulating VEGF and Cyclin D1 Expression.

Authors:  Nan Zhang; Min Zhang; Zhou Wang; Wei Gao; Zhi-Gang Sun
Journal:  J Cancer       Date:  2020-01-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.